First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That Have Returned or Not Responded to Treatment

XenCART is an autologous bispecific CD20 and CD19 CAR T cell product from Cellogen Therapeutics Pvt Ltd. This first in human Phase I study at CMC Vellore will evaluate its safety tolerability and preliminary efficacy in adults with relapsed or refractory CD19 and CD20 positive B cell malignancies including B NHL and B ALL. Patients will undergo leukapheresis 9 to 12 day manufacturing fludarabine and cyclophosphamide lymphodepletion and a single intravenous infusion. The study includes a 28 day DLT evaluation period 24 months of active follow up and long term follow up thereafter. A 3 plus 3 do

Trial Details

NCT ID
NCT07948733
Phase
PHASE1
Sponsor
Cellogen Therapeutics Pvt. Ltd.
Status
RECRUITING
Cancer Type
Burkitt Lymphoma Lymphoma
Interventions
  • Autologous bispecific CD20/CD19 CAR-T cells - 1 × 10⁶ cells/kg
  • Autologous bispecific CD20/CD19 CAR-T cells - 2 × 10⁶ cells/kg
  • Autologous bispecific CD20/CD19 CAR-T cells - 4 × 10⁶ cells/kg
Locations (sample)
  • Vellore, Tamil Nadu, India|12.9184,79.13255

Key Eligibility Criteria

  • Subjects must meet ONE of the following
  • Adults aged 18 to 65 years with relapsed or refractory CD19 and or CD20 positive B cell malignancy B ALL or B NHL
  • B ALL At least 1 prior line of systemic therapy Ph positive ALL eligible after at least 1 BCR ABL1 TKI failure Morphological relapse with at least …
  • B NHL At least 2 prior lines including an anthracycline and an anti CD20 mAb At least 1 line if auto SCT ineligible or failed Transformed histologi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Burkitt Lymphoma Lymphoma Trials on Trialify →